Discover
IMMX
Immix Biopharma, Inc.
9.88
1 x 7.51
1 x 12.58
bid
ask
+
0.05
0.51%
01:19 PM
timesize
| Ytd | 88.91% | |
| 1y | 309.96% |
9.74
day range
10.46
1.94
52 week range
11.61
| Open | 9.93 | Prev Close | 9.83 | Low | 9.74 | High | 10.46 | Mkt Cap | 703.36M |
| Vol | 751.52K | Avg Vol | 1.38M | EPS | -0.92 | P/E | N/A | Forward P/E | -3.96 |
| Beta | 0.10 | Short Ratio | 2.94 | Inst. Own | 17.64% | Dividend | N/A | Div Yield | N/A |
| Ex Div Date | N/A | Earning | 08-15 | 50-d Avg | 9.24 | 200-d Avg | 6.61 | 1yr Est | 7.00 |
Earning
| Date | For | Estimate | Reported | Surprise | surprise % |
|---|---|---|---|---|---|
| 2024-11-12 | 2024-09 | -0.16 | -0.24 | -0.08 | -50.00% |
| 2024-08-12 | 2024-06 | -0.21 | -0.15 | 0.06 | 28.57% |
| 2024-08-12 | 2024-06 | -0.21 | N/A | N/A | N/A |
| 2024-05-09 | 2024-03 | -0.23 | N/A | N/A | N/A |
| 2024-05-09 | 2024-03 | -0.23 | -0.22 | 0.01 | 4.35% |
| 2024-03-29 | 2023-12 | -0.23 | N/A | N/A | N/A |
Upgrade / Downgrade
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| 2024-10-03 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-08-19 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-07-26 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-07-09 | HC Wainwright & Co. | Upgrade | Buy | Buy |
| 2024-07-01 | HC Wainwright & Co. | Upgrade | Buy | |
| 2023-08-14 | Roth MKM | Upgrade | Buy | Buy |
Profile
Immix Biopharma, Inc., a clinical-stage biopharmaceutical company, engages in developing tissue-specific therapeutics in oncology and immune-dysregulated diseases in the United States and Australia. The company is developing IMX-110 that is in Phase 1b/2a clinical trials for the treatment of soft tissue sarcoma and colorectal cancer; and NXC-201 for relapsed/refractory multiple myeloma. It has a clinical collaboration and supply agreement with BeiGene Ltd. for a combination Phase 1b clinical trial in solid tumors of IMX-110 and anti-PD-1 Tislelizumab. Immix Biopharma, Inc., was incorporated in 2012 and is headquartered in Los Angeles, California.
Insider Holder
| Date | Name | Relation | Quantity | Description |
|---|---|---|---|---|
| 2024-05-19 | ADAMS HELEN C | Director | 174.75K | Stock Award(Grant) |
| 2024-05-19 | BUCHAN MELISSA JANE | Director | 22.46K | Stock Award(Grant) |
| 2024-08-21 | HSU JASON | Director | 4.81M | Purchase |
| 2024-05-19 | MARQUET MAGDA | Director | 66.09K | Stock Award(Grant) |
| 2024-06-06 | MORRIS GABRIEL S | Chief Financial Officer | 580.82K | Purchase |
| 2024-08-15 | NG CAREY | Director | 1.05M | Purchase |
Institution Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | AIGH Capital Management LLC | 1.12M | 2.45M | 4.08% |
| 2024-09-29 | Bleichroeder LP | 850.00K | 1.85M | 3.09% |
| 2024-09-29 | Cable Car Capital LLC | 796.10K | 1.74M | 2.89% |
| 2024-09-29 | Vanguard Group Inc | 698.54K | 1.52M | 2.54% |
| 2024-03-30 | Lynwood Capital Management Inc. | 405.00K | 882.90K | 1.47% |
| 2024-09-29 | Geode Capital Management, LLC | 150.08K | 327.18K | 0.55% |
Fund Ownership
| Report Date | Organization | Position | Value | Percentage |
|---|---|---|---|---|
| 2024-09-29 | Vanguard Total Stock Market Index Fund | 499.29K | 1.09M | 1.82% |
| 2024-09-29 | Vanguard Extended Market Index Fund | 199.25K | 434.36K | 0.72% |
| 2024-10-30 | Fidelity Extended Market Index Fund | 79.26K | 172.79K | 0.29% |
| 2024-09-29 | 360 Funds-Timber Point Global Tactical Allocation Fd | 30.00K | 65.40K | 0.11% |
| 2024-10-30 | Fidelity Total Market Index Fund | 22.27K | 48.55K | 0.08% |
| 2024-10-30 | Fidelity Series Total Market Index Fund | 18.70K | 40.76K | 0.07% |